Related references
Note: Only part of the references are listed.Potential association between COVID-19 mortality and healthcare resource availability
Yunpeng Ji et al.
LANCET GLOBAL HEALTH (2020)
Managing COVID-19 in Low- and Middle-Income Countries
Joost Hopman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Racial Health Disparities and Covid-19-Caution and Context
Merlin Chowkwanyun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Racial disparity in Covid-19 mortality rates - A plausible explanation
Yuval Tal et al.
CLINICAL IMMUNOLOGY (2020)
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Bette Korber et al.
CELL (2020)
Correlation between weather and Covid-19 pandemic in Jakarta, Indonesia
Ramadhan Tosepu et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2020)
Public preferences for corporate social responsibility activities in the pharmaceutical industry: Empirical evidence from Korea
Hankil Lee et al.
PLOS ONE (2019)
Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries
Eliana Barrenho et al.
HEALTH ECONOMICS (2019)
Analysis of new drugs registered in Brazil in view of the Unified Health System and the disease burden
Stephanie Ferreira Botelho et al.
CIENCIA & SAUDE COLETIVA (2018)
A means of improving public health in low- and middle-income countries? Benefits and challenges of international public private partnerships
L. Kostyak et al.
PUBLIC HEALTH (2017)
Private versus social incentives for pharmaceutical innovation
Paula Gonzalez et al.
JOURNAL OF HEALTH ECONOMICS (2016)
Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms
Hayley Droppert et al.
GLOBALIZATION AND HEALTH (2015)
Market size and pharmaceutical innovation
Pierre Dubois et al.
RAND JOURNAL OF ECONOMICS (2015)
Burden of disease, research funding and innovation in the UK: Do new health technologies reflect research inputs and need?
Derek Ward et al.
JOURNAL OF HEALTH SERVICES RESEARCH & POLICY (2013)
Innovation and the Burden of Disease: Retrospective Observational Study of New and Emerging Health Technologies Reported by the EuroScan Network from 2000 to 2009
Orsolina I. Martino et al.
VALUE IN HEALTH (2012)
Challenges for pharmaceutical industry: new partnerships for sustainable human health
Jackie Hunter
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES (2011)
The importance of new companies for drug discovery: origins of a decade of new drugs
Robert Kneller
NATURE REVIEWS DRUG DISCOVERY (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Knowledge sources, patent protection, and commercialization of pharmaceutical innovations
Christian Sternitzke
RESEARCH POLICY (2010)
Does the development of new medicinal products in the European Union address global and regional health concerns?
Ferran Catala-Lopez et al.
POPULATION HEALTH METRICS (2010)
A review of non-communicable disease in low- and middle-income countries
Ala Alwan et al.
INTERNATIONAL HEALTH (2009)
Market incentives and pharmaceutical innovation
Wesley Yin
JOURNAL OF HEALTH ECONOMICS (2008)
Developing drugs for developing countries
DB Ridley et al.
HEALTH AFFAIRS (2006)
Pharmaceutical innovation and the burden of disease in developing and developed countries
FR Lichtenberg
JOURNAL OF MEDICINE AND PHILOSOPHY (2005)
The corporate social responsibility of the pharmaceutical industry: Idealism without illusion and realism without resignation
KM Leisinger
BUSINESS ETHICS QUARTERLY (2005)
Market size in innovation: Theory and evidence from the pharmaceutical industry
D Acemoglu et al.
QUARTERLY JOURNAL OF ECONOMICS (2004)
Pharmaceuticals and the developing world
M Kremer
JOURNAL OF ECONOMIC PERSPECTIVES (2002)
Drug development for neglected diseases: a deficient market and a public-health policy failure
P Trouiller et al.
LANCET (2002)
Share Paper
